Fresenius SE KGaA (BIT:1FRE) - Stock Price, News & Analysis

1FRE Stock Overview

A health care company, provides products and services for chronically ill patients.

1FRE fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	3/6
Past Performance	4/6
Financial Health	3/6
Dividends	0/6

Rewards

Trading at 59.3% below our estimate of its fair value

Earnings are forecast to grow 23.72% per year

Earnings grew by 29.9% over the past year

Risk Analysis

Interest payments are not well covered by earnings

Fresenius SE & Co. KGaA Competitors

Amplifon

BIT:AMP

€5.8b

DiaSorin

BIT:DIA

€5.4b

Servizi Italia

BIT:SRI

€60.0m

Labcorp Holdings

NYSE:LH

US$18.4b

Price History & Performance

Summary of all time highs, changes and price drops for Fresenius SE KGaA
Historical stock prices
Current Share Price	€33.89
52 Week High	€34.80
52 Week Low	€23.93
Beta	1.07
11 Month Change	1.59%
3 Month Change	16.78%
1 Year Change	22.48%
33 Year Change	-14.42%
5 Year Change	-17.38%
Change since IPO	-48.96%

Recent updates

Shareholder Returns

	1FRE	IT Healthcare	IT Market
7D	1.7%	-1.7%	-3.1%
1Y	22.5%	-3.6%	17.9%

Return vs Industry: 1FRE exceeded the Italian Healthcare industry which returned -6.3% over the past year.

Return vs Market: 1FRE exceeded the Italian Market which returned 19.8% over the past year.

Price Volatility

Is 1FRE's price volatile compared to industry and market?
1FRE volatility
1FRE Average Weekly Movement	2.9%
Healthcare Industry Average Movement	3.8%
Market Average Movement	4.1%
10% most volatile stocks in IT Market	6.7%
10% least volatile stocks in IT Market	2.5%

Stable Share Price: 1FRE has not had significant price volatility in the past 3 months compared to the Italian market.

Volatility Over Time: 1FRE's weekly volatility (3%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1912	175,771	Michael Sen	www.fresenius.com

Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.

Fresenius SE & Co. KGaA Fundamentals Summary

How do Fresenius SE KGaA's earnings and revenue compare to its market cap?
1FRE fundamental statistics
Market cap	€19.13b
Earnings (TTM)	€721.00m
Revenue (TTM)	€22.63b

26.5x

P/E Ratio

0.8x

P/S Ratio

Is 1FRE overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1FRE income statement (TTM)
Revenue	€22.63b
Cost of Revenue	€17.41b
Gross Profit	€5.23b
Other Expenses	€4.51b
Earnings	€721.00m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

Nov 06, 2024

Earnings per share (EPS)	1.28
Gross Margin	23.09%
Net Profit Margin	3.19%
Debt/Equity Ratio	61.2%

How did 1FRE perform over the long term?

See historical performance and comparison

1FRE Stock Overview

Rewards

Risk Analysis

Fresenius SE & Co. KGaA Competitors

BIT:AMP

€5.8b

BIT:DIA

€5.4b

BIT:SRI

€60.0m

NYSE:LH

US$18.4b

Price History & Performance

Recent News & Updates

PAI Mid-Market Fund SCSp. managed by PAI Partners completed the acquisition of 67% stake in Vamed rehabilitation business from Fresenius SE & Co. KGaA (XTRA:FRE).

Second quarter 2024 earnings released: EPS: €0.34 (vs €0.21 loss in 2Q 2023)

First quarter 2024 earnings released: EPS: €0.49 (vs €0.61 in 1Q 2023)

PAI Mid-Market Fund SCSp. managed by PAI Partners agreed to acquire 67% stake in Vamed rehabilitation business from Fresenius SE & Co. KGaA (XTRA:FRE).

Verme family with other shareholders completed the acquisition of additional 70% stake in Clinica Ricardo Palma S.A. from Fresenius SE & Co. KGaA (XTRA:FRE).

IVIRMA Global SL and GED Iberian Private Equity, S.A., SGEIC completed the acquisition of EUVITRO S.L.U. from Fresenius SE & Co. KGaA (XTRA:FRE).

Recent updates

PAI Mid-Market Fund SCSp. managed by PAI Partners completed the acquisition of 67% stake in Vamed rehabilitation business from Fresenius SE & Co. KGaA (XTRA:FRE).

Second quarter 2024 earnings released: EPS: €0.34 (vs €0.21 loss in 2Q 2023)

First quarter 2024 earnings released: EPS: €0.49 (vs €0.61 in 1Q 2023)

PAI Mid-Market Fund SCSp. managed by PAI Partners agreed to acquire 67% stake in Vamed rehabilitation business from Fresenius SE & Co. KGaA (XTRA:FRE).

Verme family with other shareholders completed the acquisition of additional 70% stake in Clinica Ricardo Palma S.A. from Fresenius SE & Co. KGaA (XTRA:FRE).

IVIRMA Global SL and GED Iberian Private Equity, S.A., SGEIC completed the acquisition of EUVITRO S.L.U. from Fresenius SE & Co. KGaA (XTRA:FRE).

German Fresenius Reportedly Seeks to Sell Vamed Reha

Investor sentiment improves as stock rises 18%

Fresenius SE & Co. KGaA to Report Fiscal Year 2023 Final Results on Mar 14, 2024

IVIRMA Global SL and GED Iberian Private Equity, S.A., SGEIC agreed to acquire EUVITRO S.L.U. from Fresenius SE & Co. KGaA (XTRA:FRE) for €500 million.

Third quarter 2023 earnings released: €0.72 loss per share (vs €0.57 profit in 3Q 2022)

Fresenius SE & Co. KGaA to Report Q2, 2024 Results on Jul 31, 2024

KKR in Talks to Buy Eugin from Fresenius

Fresenius Reportedly Plans to Offload Digital Subsidiary Curalie

New major risk - Financial position

Second quarter 2023 earnings released: EPS: €0.14 (vs €0.68 in 2Q 2022)

Fresenius SE & Co. KGaA to Report Q3, 2023 Results on Nov 02, 2023

Fresenius Se & Co. Kgaa Proposes Dividend for 2022

Upcoming dividend of €0.92 per share at 3.3% yield

First quarter 2023 earnings released: EPS: €0.61 (vs €0.74 in 1Q 2022)

Fresenius SE & Co. KGaA to Report Q1, 2023 Results on May 09, 2023

Full year 2022 earnings released: EPS: €2.44 (vs €3.26 in FY 2021)

Fresenius SE & Co. KGaA, Annual General Meeting, May 17, 2023

QIC Reportedly Set to Clinch Healius Day Hospital Unit for $140 Million Plus

Third quarter 2022 earnings released: EPS: €0.57 (vs €0.74 in 3Q 2021)

Brookfield Reportedly Drops Out of Race to Buy Healius

Fresenius SE Announces Chief Financial Officer Changes

Fresenius SE & Co. KGaA Announces Michael Sen as CEO on October 1, 2022 Succeeding Stephan Sturm

Second quarter 2022 earnings released: EPS: €0.68 (vs €0.84 in 2Q 2021)

Healius Reportedly Launches Day Surgery Sale Process

Fresenius Kabi Introduces Generic Iodixanol Contrast Media Agent

Upcoming dividend of €0.92 per share

First quarter 2022 earnings released: EPS: €0.74 (vs €0.78 in 1Q 2021)

Investor sentiment deteriorated over the past week

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Fresenius SE & Co. KGaA Provides Earnings Guidance for the Year 2022

Third quarter 2021 earnings released: EPS €0.74 (vs €0.77 in 3Q 2020)

Second quarter 2021 earnings released: EPS €0.84 (vs €0.74 in 2Q 2020)

Upcoming dividend of €0.88 per share

First quarter 2021 earnings released: EPS €0.78 (vs €0.82 in 1Q 2020)

Full year 2020 earnings released: EPS €3.06 (vs €3.38 in FY 2019)

New 90-day high: €40.03

Fresenius SE & Co. KGaA to Report Q1, 2021 Results on May 07, 2021

Fresenius SE & Co. KGaA, Annual General Meeting, May 21, 2021

Market bids up stock over the past week

Third-quarter earnings released: Revenue misses expectations

Third quarter earnings released

New 90-day low: €36.38

New 90-day low - €38.61

Upcoming Dividend of €0.84 Per Share